Xcout IntelBioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Subscribe to see BioAge Labs, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BioAge Labs, Inc. at a glance
BioAge Labs, Inc. is a biotech company headquartered in Emeryville, United States. It is publicly listed (BIOA) with a market capitalisation of $356.9M. Xcout tracks 23 named people at BioAge Labs, Inc., including Dov A. Goldstein (Chief Financial Officer).
BioAge Labs, Inc. leadership
- Dov A. GoldsteinChief Financial Officer
- Paul D. RubinChief Medical Officer & Executive Vice President of Research
- Ann C. NealeChief Development Officer
- Peng LeongChief Business Officer & Therapeutic Area Head of Brain Aging
- SullivanChief Strategy Officer
- Kristen FortneyCo-Founder, Chief Executive Officer, President, Treasurer, Secretary & Director
17 more named people on record for BioAge Labs, Inc., with roles, board committees and tenure — see the full roster →
BioAge Labs, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $194.4M | 13 named | |
| Series C | $90M | 12 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
BioAge Labs, Inc. competitors
A few of BioAge Labs, Inc.'s closest competitors — see the full list of competitors and alternatives →
Spring Discovery (also known as Spring Science) is a biotechnology research company founded in 2017 and based in San Carlos, California. The company focuses on therapeutics and drug discovery targeting age-related diseases.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Biophytis is a clinical-stage biotechnology company that develops transformative therapies to impact longevity, slow aging, and improve sustainable health. The company utilizes a research platform to discover new drug candidates, with its lead candidate BIO101 being evaluated for the treatment of conditions such as sarcopenia and obesity.
Carmot Therapeutics, Inc. is a biopharmaceutical company headquartered in Berkeley, California, focused on discovering and developing innovative treatments for metabolic diseases and obesity.
Deciduous Therapeutics, Inc. is a biotechnology startup located in San Francisco, California, focused on developing novel therapeutics targeting aging and immune dysfunction.
Gordian Biotechnology is a biotechnology research company headquartered in South San Francisco, California. The company focuses on curing age-related diseases through in vivo target discovery and functional genomics platforms.
Get BioAge Labs, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BioAge Labs, Inc. in Xcout Intel
- 23 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access